Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
<h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0119911 |
id |
doaj-847f16d540124c6cbca2a8fdfed7ffc5 |
---|---|
record_format |
Article |
spelling |
doaj-847f16d540124c6cbca2a8fdfed7ffc52021-03-04T08:31:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011991110.1371/journal.pone.0119911Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.Tomasz HawroAndrzej BoguckiMaria Krupińska-KunMarcus MaurerAnna Woźniacka<h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important aPL antigen, are thought to play a role in some forms of NPSLE. As of yet, their specific roles in NPSLE manifestations remain to be elucidated.<h4>Methodology/principal findings</h4>57 SLE patients (53 women) were assessed for LA, aCL and anti-β2GPI twice, to determine persistent positivity. All patients were examined by neurology and psychiatry specialists. 69 healthy subjects were assessed as controls. NPSLE was diagnosed in 74% of patients. Headaches were the most prevalent manifestation of NPSLE (39%), followed by cerebrovascular disease (CVD) (23%), depressive disorders (19.0%), and seizures (14%). NPSLE and non-NPSLE patients showed comparable SLE activity and corticosteroid use. In 65% of patients neuropsychiatric manifestations preceded SLE diagnosis. aPL profiles of NPSLE patients and non-NPSLE patients were similar. Headaches and ischemic stroke were independently associated with anti-β2GPI-IgM (OR=5.6; p<0.05), and seizures were linked to anti-β2GPI-IgG (OR=11.3; p=0.01).<h4>Conclusions</h4>In SLE patients, neuropsychiatric manifestations occur frequently and early, often before the disease is diagnosed. Autoantibodies to β2GPI are linked to non-specific headaches, ischemic stroke and seizures, and show a better predictive value than aCL and LA. These findings may help to improve the diagnosis of NPSLE and should prompt further studies to characterize the role of anti-β2GPI in the pathogenesis of this condition.https://doi.org/10.1371/journal.pone.0119911 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tomasz Hawro Andrzej Bogucki Maria Krupińska-Kun Marcus Maurer Anna Woźniacka |
spellingShingle |
Tomasz Hawro Andrzej Bogucki Maria Krupińska-Kun Marcus Maurer Anna Woźniacka Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. PLoS ONE |
author_facet |
Tomasz Hawro Andrzej Bogucki Maria Krupińska-Kun Marcus Maurer Anna Woźniacka |
author_sort |
Tomasz Hawro |
title |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. |
title_short |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. |
title_full |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. |
title_fullStr |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. |
title_full_unstemmed |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. |
title_sort |
intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2gpi antibodies in patients with systemic lupus erythematosus. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
<h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important aPL antigen, are thought to play a role in some forms of NPSLE. As of yet, their specific roles in NPSLE manifestations remain to be elucidated.<h4>Methodology/principal findings</h4>57 SLE patients (53 women) were assessed for LA, aCL and anti-β2GPI twice, to determine persistent positivity. All patients were examined by neurology and psychiatry specialists. 69 healthy subjects were assessed as controls. NPSLE was diagnosed in 74% of patients. Headaches were the most prevalent manifestation of NPSLE (39%), followed by cerebrovascular disease (CVD) (23%), depressive disorders (19.0%), and seizures (14%). NPSLE and non-NPSLE patients showed comparable SLE activity and corticosteroid use. In 65% of patients neuropsychiatric manifestations preceded SLE diagnosis. aPL profiles of NPSLE patients and non-NPSLE patients were similar. Headaches and ischemic stroke were independently associated with anti-β2GPI-IgM (OR=5.6; p<0.05), and seizures were linked to anti-β2GPI-IgG (OR=11.3; p=0.01).<h4>Conclusions</h4>In SLE patients, neuropsychiatric manifestations occur frequently and early, often before the disease is diagnosed. Autoantibodies to β2GPI are linked to non-specific headaches, ischemic stroke and seizures, and show a better predictive value than aCL and LA. These findings may help to improve the diagnosis of NPSLE and should prompt further studies to characterize the role of anti-β2GPI in the pathogenesis of this condition. |
url |
https://doi.org/10.1371/journal.pone.0119911 |
work_keys_str_mv |
AT tomaszhawro intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus AT andrzejbogucki intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus AT mariakrupinskakun intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus AT marcusmaurer intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus AT annawozniacka intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus |
_version_ |
1714807794641666048 |